LeMaitre Vascular to Present at Three Investor Conferences in November
BURLINGTON, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in three investor conferences in November.
David Roberts, President, is scheduled to present at the Stifel Healthcare Conference in New York on Wednesday, November 16 at the Lotte New York Palace Hotel. The Company’s presentation is scheduled to begin at 11:45 am ET.
JJ Pellegrino, Chief Financial Officer, is scheduled to present at the Three Part Advisors Southwest IDEAS Conference in Dallas on Wednesday, November 16 at the InterContinental Dallas Hotel. The Company’s presentation is scheduled to begin at 11:20 am CT.
George W. LeMaitre, Chairman & CEO, is scheduled to present at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York on Thursday, November 17 at the Westin Grand Central Hotel. The Company’s presentation is scheduled to begin at 3:00 pm ET.
For more information or to register, please visit the conference websites at www.stifel.com, www.threepartadvisors.com and www.canaccordgenuity.com.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
Contact: LeMaitre Vascular, Inc. Steven Chehames Investor Relations +1-781-425-1659 schehames@lemaitre.com http://www.lemaitre.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
